Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
This study is creating a registry and sample bank for people with plasma cell dyscrasias (diseases affecting certain white blood cells), including multiple myeloma, AL amyloidosis, and MGUS (monoclonal gammopathy of undetermined significance). Researchers are collecting information, blood samples, and bone marrow tissue to better understand these conditions. The goal is to improve the quality and length of life for patients in Ohio by tracking treatments, complications, and how long people live. You may be able to join if you are 18 or older and have a diagnosis of a plasma cell dyscrasia. The study aims to develop this resource over three years.
- Study design
- This is an observational study, meaning researchers are collecting information without providing specific treatments. It plans to enroll up to 5000 participants.
- What's involved
- Participation involves tissue procurement (taking samples) at diagnosis, during routine check-ups, or if the disease returns.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal of developing the data and sample resource is measured at up to 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Don Benson, MD · PRINCIPAL_INVESTIGATOR · Ohio State University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Develop a data and sample resource that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality of patients diagnosed or living with Multiple Myeloma in the state of Ohioup to 3 years